8-K: Heartflow Unveils Strong Growth, AI Innovation & Market Expansion

Heartflow, Inc. presented robust financial performance, significant advancements in AI-powered coronary artery disease diagnostics, and strategic plans for market expansion at an investor conference.

Summary

• Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) diagnostics.
• The company reported $162 million in Last Twelve Months (LTM) revenue as of Q3 2025.
• FFRCT base business revenue grew 41% year-over-year in Q3 2025.
• Non-GAAP gross margin for LTM Q3 2025 was 76%, a 2-point improvement year-over-year.
• The U.S. Total Addressable Market (TAM) is currently estimated at $5 billion, with a mid-term expansion target to $6 billion by entering asymptomatic markets.
• Heartflow has an installed base of 1,465 U.S. accounts and over 25,000 active physician customers as of January 1, 2026.
• The company's Plaque Analysis product has 489 U.S. installed bases as of January 1, 2026, and achieved Category 1 CPT code reimbursement effective January 1, 2026, covering over 70% of U.S. lives.
• Heartflow FFRCT covers 99.5% of U.S. lives with Category 1 CPT code reimbursement and has treated over 500,000 patients globally.
• The company holds over 500 patents and has more than 600 peer-reviewed publications.
• Cash and cash equivalents stood at $291 million.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with strong revenue growth, improving margins, significant market penetration, and clear strategic plans for future expansion and product innovation. While the company is still operating at a net loss, the trajectory of financial improvement and commercial milestones are highly encouraging. The extensive clinical validation and intellectual property also contribute to a strong positive sentiment.

Positives

• Strong LTM Q3 2025 revenue of $162 million, indicating significant commercial performance.
• Robust 41% year-over-year revenue growth in the FFRCT base business for Q3 2025.
• Improved non-GAAP gross margin of 76% for LTM Q3 2025, a 2-point increase year-over-year, with a long-term target of over 80%.
• Significant market penetration growth, with U.S. installed base increasing from 562 in 2022 to 1,465 in 2025, and account market penetration reaching 46%.
• Successful commercialization and reimbursement for Plaque Analysis, with 489 U.S. installed bases and Category 1 CPT code coverage for over 70% of U.S. lives effective January 1, 2026.
• Heartflow FFRCT is widely adopted, covering 99.5% of U.S. lives and used in over 1,800 accounts worldwide.
• The company possesses a strong intellectual property portfolio with over 500 patents and extensive clinical validation with over 600 peer-reviewed publications.
• Strategic roadmap includes new product innovations like Next Gen FFRCT, Next Gen Plaque, and PCI Navigator, expanding the end-to-end CAD care platform.
• Substantial cash and cash equivalents of $291 million provide financial flexibility.

Negatives

• The company is still operating at a non-GAAP net loss of $(13.2) million for Q3 2025 and $(50.1) million for the nine months ended September 30, 2025.
• Non-GAAP operating expenses as a percentage of revenues remain high at 105.6% for Q3 2025, indicating continued investment in growth.
• Heartflow Plaque Staging is currently an investigational-only framework, and its safety and effectiveness have not been reviewed by the FDA.
• The company is dependent on the success of its primary product, Heartflow FFRCT Analysis, and the willingness of healthcare providers to adopt new practices.
• Significant competition exists in a rapidly changing technological environment.

Risks

• Ability to achieve or sustain profitability.
• Dependence on the success of the single product, Heartflow FFRCT Analysis.
• Willingness of healthcare providers to change their standard practice regarding the evaluation of coronary artery disease.
• Impact on adoption if third-party payors, including government payors, do not cover or provide adequate reimbursement.
• Concentration of the customer base.
• Significant competition in an environment of rapid technological change.
• Nascent nature of the commercialization of Heartflow Plaque Analysis.
• Risks associated with the use and development of artificial intelligence models.
• Ability to properly manage future growth.
• Disruption by catastrophic events.
• Damage to or disruption of information technology systems.
• Security breaches that cannot be anticipated or successfully defended.
• Extensive regulatory requirements to bring products to market.
• Risks that third parties could develop commercial technology and products similar or identical to Heartflow's.
• Ability to obtain and maintain sufficient intellectual property protection or avoid claims of infringement.
• Additional capital might not be available on favorable terms or at all.

Future Outlook

Heartflow anticipates continued revenue growth and non-GAAP gross margin expansion, targeting over 80% long-term gross margin through improved automation, production efficiency, and increased case volumes, particularly from Plaque revenues. The company plans a mid-term U.S. Total Addressable Market expansion to $6 billion by 2030 through three targeted randomized controlled trials (RCTs) in high-risk asymptomatic populations (Prior MI/PCI, Elevated CACs, Prior Symptoms w/ Plaque), with enrollments starting in 1H 2026, 2H 2026, and 1H 2027, respectively. The Heartflow Navigator planning tool is expected to launch in 2026, with the primary endpoint for its P4 Study anticipated in 2H 2026.

Management Comments

• We are the leader in AI technology for coronary artery disease (CAD).
• Heartflow is creating a new standard of care for CAD.
• Our near-term strategy focuses on a strong core business with emerging plaque opportunity, while our mid-term strategy targets TAM expansion into asymptomatic markets.
• We are uniquely positioned to win with superior clinical data, service, and scale.

Industry Context

Heartflow operates in the rapidly evolving medical technology and diagnostic imaging sector, specifically targeting coronary artery disease (CAD), which remains the leading cause of death in the U.S. The industry is experiencing a significant shift towards AI-enabled advanced imaging, mirroring transformations seen in cancer management. Heartflow's focus on non-invasive, highly accurate diagnostics positions it to disrupt traditional, less effective standard-of-care methods that suffer from high false positive and negative rates. The company's strategy to expand into asymptomatic high-risk populations aligns with broader healthcare trends emphasizing preventative care and early detection to reduce long-term healthcare costs and improve patient outcomes.

Comparison to Industry Standards

• Heartflow's FFRCT is cited as the 'most accurate non-invasive test for CAD,' outperforming traditional methods like SPECT, Stress Echo, and Exercise Stress, which have high false negative (30%) and false positive (55%) rates.
• The company's AI-enabled CCTA platform offers a 67% lower radiation dose and 75% faster procedure time compared to SPECT, a common non-invasive test.
• Heartflow's technology has demonstrated a 41% lower rate of death or myocardial infarction (MI) at 5 years, a significant improvement over outcomes associated with the status quo.
• The Plaque Analysis product boasts 95% accuracy against the invasive gold standard, a benchmark for diagnostic precision in the industry.
• The company's approach to CAD management is endorsed in society guidelines across the US, UK, Europe, and Japan, indicating strong clinical acceptance compared to emerging or unproven technologies.
• Heartflow's projected $3 billion in annual Medicare cost savings highlights its potential to offer a more cost-effective solution than current diagnostic pathways.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, market expansion, and improving profitability trajectory. The company's robust IP and clinical validation could also enhance long-term value.
• Patients: Improved diagnostic accuracy, lower radiation exposure, faster procedure times, and better long-term outcomes (41% lower rate of death or MI at 5 years) for patients with coronary artery disease.
• Healthcare Providers: Enhanced efficiency (26% increase in CCTA reader efficiency), higher accuracy (78% increase in identifying treatable patients, 75% reduction in false positives), and seamless integration into existing workflows (PACS/EMR) without capital expenditure.
• Payors (e.g., Medicare): Potential for significant cost savings, estimated at $3 billion annually for Medicare, due to reduced unnecessary diagnostic procedures and improved patient management.
• Employees: Continued growth and product innovation may lead to increased opportunities and stability within the company.

Next Steps

• Initiate ~5,000 patients in the NAVIGATE-PCI Registry for Heartflow Navigator in 1H 2026.
• Launch Heartflow Navigator in 2026.
• Expect Primary Endpoint for P4 Study (1,104 patient RCT) for Heartflow Navigator in 2H 2026.
• Begin enrollment for RCT #1 (Prior MI/PCI) for TAM expansion in 1H 2026.
• Begin enrollment for RCT #2 (Elevated CACs) for TAM expansion in 2H 2026.
• Begin enrollment for RCT #3 (Prior Symptoms w/ Plaque) for TAM expansion in 1H 2027.
• Continue to drive gross margin expansion towards the >80% long-term target through automation and volume leverage.
• Expand U.S. TAM by $6 billion before 2030 through targeted RCTs in asymptomatic markets.

Key Dates

Recommendation

Heartflow demonstrates exceptional growth metrics, with 41% YoY revenue growth in its core business and a significant expansion in its installed base. The company's AI-powered diagnostic tools are clinically validated, endorsed by major medical societies, and show superior accuracy and patient outcomes compared to traditional methods. The successful commercialization and Category 1 CPT code reimbursement for Plaque Analysis, effective January 1, 2026, is a major catalyst for future revenue. With a clear roadmap for TAM expansion into asymptomatic markets, strong IP, and a healthy cash position, Heartflow is well-positioned for substantial long-term growth and market leadership in CAD diagnostics. While still unprofitable, the improving gross margins and operational leverage indicate a clear path towards profitability, making it a compelling 'strong buy' for investors with a long-term horizon.

Keywords

Coronary Artery Disease, CAD, Heartflow, FFRCT, Plaque Analysis, AI in Healthcare, Medical Devices, Cardiology, Diagnostic Imaging, CCTA, Investor Presentation, SEC Filing, Healthcare Technology, Artificial Intelligence, Medical Diagnostics